 Home > Popular Keywords > Keyword List P > p plus china

p plus china

All the latest news related p plus china are here. We share widely topic articles of p plus china on echemi.com.

In 2020, China's oil and natural gas supply is in short supply

 Time of Update: 2022-05-28

Among them, petroleum processing, coking, nuclear fuel processing, chemical raw materials and chemical products manufacturing, and petroleum and natural gas extraction industries consume relatively large amounts of crude oil.
Kintor Pharma Announces Completion of Subject Enrollment in China Phase II Clinical Trial of Furitax for the Treatment of Female Hair Loss

 Time of Update: 2022-05-27

for female androgenetic alopecia (AGA). The phase II clinical trial in China took just over 4 months to complete the required enrollment of 160 subjects on March 4, 2022 . >
The world's first basal insulin GLP-1RA injection Novozymes(R) launched in China

 Time of Update: 2022-05-27

The recently launched Novoyi® (insulin degludec liraglutide injection) is the world's first basal insulin GLP-1RA injection, which is suitable for adult patients with type 2 diabetes with poor blood sugar control.
The global food crisis intensifies, how should China respond?

 Time of Update: 2022-05-27

" Meng Wei said that in the next step, the National Development and Reform Commission and the National Grain Material Reserve Bureau will adhere to comprehensive policies and precise control to effectively ensure the supply of domestic grain markets .
Samsung Gathers China's First Marine Surveillance Monitoring Radar Satellite Constellation Officially Completed

 Time of Update: 2022-05-27

12 imaging modes, covering traditional strip imaging mode and scanning imaging mode, as well as wave imaging mode and global observation imaging mode for ocean applications. It is the synthetic aperture radar satellite with the most imaging
China Resources Pharma's China Pharmaceutical Research Innovative Drug NIP003 Tablets Obtained Clinical Approval

 Time of Update: 2022-05-27

Institute, a subsidiary of China Resources Pharma, obtained the "Notice of Drug Clinical Trial Approval" issued by the NMPA, and was approved for clinical use in the prevention of arteriovenous thrombosis. test
CStone Announces the Approval of Pujihua(R) (pratinib capsules) in China for the treatment

 Time of Update: 2022-05-27

Jiang Ningjun, Chairman and Chief Executive Officer of CStone, said: "We are delighted that the expanded indications of Pujihua® have been approved, bringing new treatment options to patients with RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer in China.
Luye Pharma Submits New Drug Application for Lurbinectedin in Hong Kong, China

 Time of Update: 2022-05-27

, including all indications for small cell lung cancer . In addition, Luye Pharma has the right to request PharmaMar to transfer the production technology of Lurbinectedin preparations to be produced
Prof. Wang Ying: Advances in the treatment of acute myeloid leukemia 2021 China Oncology Congress

 Time of Update: 2022-05-27

Conference on Oncology (CCO) held online from April 14 to 17, 2022, Professor Wang Ying from the Hospital of Hematology, Chinese Academy of Medical Sciences, with the title of "Progress in the Treatment of Acute Myeloid Leukemia", introduced the current
China's renewable energy indicators rank first in the world

 Time of Update: 2022-05-27

　　"According to the latest statistics, as of the end of 2019, my country’s cumulative grid-connected installed capacity of renewable energy reached 790 million kilowatts, of which hydropower
Inventory of new drugs approved for listing in China, the United States and Europe in February

 Time of Update: 2022-05-27

　　In February, China, the United States and Europe approved a total of 12 new drugs for the market .
in the Treatment of Relapsed/Refractory Waldenström's Macroglobulinemia in China

 Time of Update: 2022-05-27

BEIJING, March 14, 2022 /PRNewswire/ -- Nuocheng Jianhua, a high-tech biopharmaceutical company, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products
Fosun Pharma, whose R&D investment ranks among the top 3 in China, is attacking everywhere

 Time of Update: 2022-05-26

So far, Fosun Pharma has completed the final piece of the jigsaw puzzle in the prevention and treatment of the new crown, becoming the first and only domestic pharmaceutical company with vaccines, oral drugs and antigen detection products .
A new drug for the treatment of hyperammonemia, Kaglutamic acid dispersible tablets, was declared for listing in China

 Time of Update: 2022-05-26

According to public information, this is a rare disease treatment product called Carbaglu, which was initially approved overseas for hyperammonemia caused by N-acetylglutamate synthase (NAGS) deficiency .
China's over 100 billion pharmaceutical companies

 Time of Update: 2022-05-26

Industrial chain extension: integration and sharing platform Sinopharm Holding, Shanghai Pharmaceuticals and China Resources Pharma, represented by state-owned holdings, have adopted a strategic layout of upstream and downstream integration, but the focus of the companies is different .
Genting Xinyao submits a new drug marketing authorization application for goxatuzumab in Hong Kong, China

 Time of Update: 2022-05-26

On March 31, Genting Sunyao announced that it had submitted a New Drug Application (NDA) for sacituzumab govitecan to the Department of Health of the Hong Kong Special Administrative Region
China Energy Construction: Won a large number of projects!

 Time of Update: 2022-05-26

The winning bid section has a total capacity of 700 MW, mainly including the design, procurement and construction of 140 5 MW wind turbines, a 220 kV booster station and related supporting roads and power collection lines .
National Medical Insurance Administration: China has vaccinated 3.2 billion doses of vaccines, costing more than 120 billion yuan

 Time of Update: 2022-05-25

negotiated with the company many times, and pushed the company to continuously reduce the price, which has been reduced to about 40 yuan/dose and 20 yuan/dose . At the same time, cooperate
China's pharmaceutical and life sciences industry M&A transaction volume hits record high in 2021

 Time of Update: 2022-05-25

The report predicts that China's aging population and the impact of the new crown epidemic will continue to increase market demand in the pharmaceutical and life science industries, and the long-term trend will remain positive .
AbbVie's JAK Inhibitor "Upatinib" Approved in China for the Third Indication

 Time of Update: 2022-05-25

upadatinib extended-release tablets was approved for the treatment of active patients with poor efficacy or intolerance to one or more DMARDs. Psoriatic arthritis (PsA) in adults . >

Related Keywords

in lu lu pakistan gc lu lu n43 lu xiaofeng lu hsw lu 71 lu dotatate

Go to Page

Hot Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

punchout catalog(268)

propranolol extended release(294)

protocatechuic acid(290)

psychomotor agitation(284)

propranolol generic(294)

psu application(277)

provent systems(289)

propylene glycol density(214)

puromycin selection(278)

prothrombin activator(285)

What's trending

Top Keywords

p gp inducers list

perchloric acid 70

p&2

prudential equity group

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

p plus china

Related Tags

Related Keywords